SCHEMBL3543246

SCHEMBL3543246

C=CCCc1cc(C(=O)OC)cc(OC)c1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.44
KDM4E B2RXH2 3/20 0.44
CYP3A4 P08684 2/20 0.42
MAPT P10636 2/20 0.41
TPMT P51580 1/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
PSMB11 A5LHX3 1/20 0.40
PSMA7 O14818 1/20 0.40
PSMB1 P20618 1/20 0.40
PSMA1 P25786 1/20 0.40
PSMA2 P25787 1/20 0.40
PSMA3 P25788 1/20 0.40
PSMA4 P25789 1/20 0.40
PSMB8 P28062 1/20 0.40
PSMB9 P28065 1/20 0.40
PSMA5 P28066 1/20 0.40
PSMB4 P28070 1/20 0.40
PSMB6 P28072 1/20 0.40
PSMB5 P28074 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3550555 0.87 TSHR (0.45) TSHRKDM4ECYP3A4MAPTTPMT
SCHEMBL3543111 0.87 TSHR (0.47) TSHRKDM4ECYP3A4MAPTTPMT
SCHEMBL3540602 0.85 TSHR (0.43) TSHRKDM4ECYP3A4MAPTTPMT
SCHEMBL3546331 0.85 TSHR (0.43) TSHRKDM4ECYP3A4MAPTTPMT
SCHEMBL3544790 0.84 TSHR (0.43) TSHRKDM4ECYP3A4MAPTTPMT
SCHEMBL3544793 0.84 TSHR (0.43) TSHRKDM4ECYP3A4MAPTTPMT
SCHEMBL3546673 0.82 PPARG (0.53) TSHRKDM4ECYP3A4MAPTTPMT
SCHEMBL3549887 0.80 CYP4A11 (0.49) TSHRKDM4ECYP3A4MAPTTPMT
SCHEMBL3545411 0.80 ALOX5 (0.50) TSHRKDM4ECYP3A4MEN1KMT2A
SCHEMBL3546446 0.79 TSHR (0.45) TSHRKDM4ECYP3A4MAPTTPMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE TSHR 3540/4885KDM4E 2323/4885CYP3A4 3888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.